Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C67H115N21O23S |
| Molecular Weight | 1614.822 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O
InChI
InChIKey=GLXYOFXNKBTMQL-YKCHQESGSA-N
InChI=1S/C67H115N21O23S/c1-7-34(4)52(86-55(99)37(17-12-23-74-67(72)73)78-62(106)51(33(2)3)85-54(98)36(70)20-26-112-6)63(107)80-39(16-9-11-22-69)65(109)87-24-13-18-45(87)60(104)75-30-48(92)77-43(31-89)58(102)76-35(5)53(97)81-40(27-47(71)91)56(100)79-38(15-8-10-21-68)64(108)88-25-14-19-46(88)61(105)84-44(32-90)59(103)82-41(28-49(93)94)57(101)83-42(66(110)111)29-50(95)96/h33-46,51-52,89-90H,7-32,68-70H2,1-6H3,(H2,71,91)(H,75,104)(H,76,102)(H,77,92)(H,78,106)(H,79,100)(H,80,107)(H,81,97)(H,82,103)(H,83,101)(H,84,105)(H,85,98)(H,86,99)(H,93,94)(H,95,96)(H,110,111)(H4,72,73,74)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1
| Molecular Formula | C67H115N21O23S |
| Molecular Weight | 1614.822 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 5 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:12:49 GMT 2025
by
admin
on
Tue Apr 01 18:12:49 GMT 2025
|
| Record UNII |
3K6A6FJ98O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
613417
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
||
|
FDA ORPHAN DRUG |
622517
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
||
|
FDA ORPHAN DRUG |
664918
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3K6A6FJ98O
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
PRIMARY | |||
|
134687212
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
PRIMARY | |||
|
C95890
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
PRIMARY | |||
|
485818-40-4
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
PRIMARY | |||
|
PIF-1
Created by
admin on Tue Apr 01 18:12:49 GMT 2025 , Edited by admin on Tue Apr 01 18:12:49 GMT 2025
|
PRIMARY | Human (80119 ) Summary: PIF1 is a 5-prime-to-3-prime DNA helicase that negatively regulates telomerase (see TERT; MIM 187270), a reverse transcriptase that maintains telomere length (Zhang et al., 2006 (PubMed 16522649) |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
SummaryThis gene encodes a DNA-dependent adenosine triphosphate (ATP)-metabolizing enzyme that functions as a 5' to 3' DNA helicase. The encoded protein can resolve G-quadruplex structures and RNA-DNA hybrids at the ends of chromosomes. It also prevents telomere elongation by inhibiting the actions of telomerase. Alternative splicing and the use of alternative start codons results in multiple isoforms that are differentially localized to either the mitochondria or the nucleus. (provided by RefSeq, Nov 2013)
|